Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Tokyo, Japan, October 17, 2011 - Astellas Pharma Inc. (Tokyo:4503,“Astellas”) announced that the Societe Internationale d’Urologie (SIU) presented its senior science advisor (and former...
Tokyo, September 28, 2011 -Astellas Pharma Inc. (Tokyo:4503, “Astellas”) announced that it has decided to discontinue the global development of darexaban maleate (generic name, development...
Astellas Pharma Inc. (Headquarters, Tokyo; President & CEO, Yoshihiko Hatanaka) today announced that the administration of the seasonal influenza HA vaccine ASP7374 (former code: UMN-0502) was...
Astellas Pharma Inc. (“Astellas Pharma”; Headquarters: Chuo-ku, Tokyo; President and CEO: Yoshihiko Hatanaka) and sanofi-aventis K.K. (“sanofi-aventis”; Headquarters: Shinjuku-ku, Tokyo;...
Tokyo, Japan, September 7, 2011 - Astellas Pharma Inc. (Tokyo:4503,“Astellas”) announced the donation of three high-standard ambulances to local municipalities in Japan. The numbers of calls...
Follow us
